[go: up one dir, main page]

WO2011079971A2 - Produit cosmétique, contenant euk-134 et/ou euk-118, et au moins une substance traitante - Google Patents

Produit cosmétique, contenant euk-134 et/ou euk-118, et au moins une substance traitante Download PDF

Info

Publication number
WO2011079971A2
WO2011079971A2 PCT/EP2010/061811 EP2010061811W WO2011079971A2 WO 2011079971 A2 WO2011079971 A2 WO 2011079971A2 EP 2010061811 W EP2010061811 W EP 2010061811W WO 2011079971 A2 WO2011079971 A2 WO 2011079971A2
Authority
WO
WIPO (PCT)
Prior art keywords
euk
hair
weight
acid
preferred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2010/061811
Other languages
German (de)
English (en)
Other versions
WO2011079971A3 (fr
Inventor
Melanie Giesen
Erik Schulze Zur Wiesche
Volker Scheunemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henkel AG and Co KGaA
Original Assignee
Henkel AG and Co KGaA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henkel AG and Co KGaA filed Critical Henkel AG and Co KGaA
Publication of WO2011079971A2 publication Critical patent/WO2011079971A2/fr
Publication of WO2011079971A3 publication Critical patent/WO2011079971A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/10—Preparations for permanently dyeing the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists

Definitions

  • the invention relates to cosmetic compositions containing EUK-134 and / or EUK-1 18 and at least one conditioner, as well as the use of EUK-134 and / or EUK-1 18 for influencing the natural pigmentation process of skin and / or skin appendages.
  • hair has a psychosocial function that should not be underestimated.
  • they serve as a means of interpersonal communication and are a sign of their own individuality. Changes, such as the graying, can lead to a massive impairment of the self-confidence of the person concerned.
  • Pigmentation in the hair follicle is controlled by a defined complex set of molecular signals. Since melanogenesis in gray follicles is obviously influenced, it can be assumed that parts of this network are modified in the gray follicle. A sequelae is the reduction in melanin synthesis, which leads to graying of the follicle.
  • the complex set of molecular signals affecting melanogenesis includes, among others, the expression of MCR1 (melanocortin receptor 1), gp100 and ckit. MCR1 and ckit are receptors that relay key melanogenesis signals through the binding of their alpha-melanocyte stimulating hormone (alpha-MSH) and stem cell factor (SCF) ligands into the cell's interior.
  • alpha-MSH alpha-melanocyte stimulating hormone
  • SCF stem cell factor
  • Gp100 is a protein of the melanosomal membrane and also regulates other melanogno-relevant proteins. Since these parameters are of essential importance in hair follicle pigmentation, it is advantageous to influence these parameters if the application of a test formulation is intended to maintain or reactivate melanin synthesis in the hair follicle cells. Maintaining the pigmentation and thus the youthfulness of the hair through suitable formulations of active ingredients is a challenge for cosmetic research.
  • the active substance EUK-134 chloro [[2,2 '- [1,2-ethanediylbis [(nitrilo-CN) methylidyne]] to [6-methoxyphenolato-KO]]] - manganese, ethylbisiminoethylguajacol-manganese chloride, Ethyl bisiminoethyl guaiacol manganese complex, 2,2 '- [1,2-ethanediylbis (nitrilomethylidyne) bis [6-methoxy] phenol manganese complex) exhibits an anti-oxidative effect.
  • the active substance EUK-1 18 ((acetato-KO) [[2,2 '- [1,2-ethanediylbis [(nitrilo-CN) -methylidyne] bis [3,5-dimethoxyphenolato-KO]] (2-) ] manganese) is structurally analogous to EUK 134 and also has anti-oxidative properties.
  • WO 2003/103616 describes the use of an active substance which mimics the activity of DOPAChrom tautomerase, to protect the melanocytes of the hair follicle from cytotoxic agents, in particular those which are associated with oxidative stress (inter alia TNF alpha, TGF beta, IL1 beta etc .). In addition to many other active substances is called anti-oxidative mimic EUK-8.
  • the object of the present invention is therefore to provide active compounds or active agent combinations and compositions containing them which are suitable for influencing the natural pigmentation process, in particular in the hair or hair follicle, without the described disadvantages of the methods known in the prior art to influence the hair color or degree of hair graying and youthful appearance of the hair. Furthermore, there is a need for such agents which, in addition to influencing the natural pigmentation process, improve the skin and / or hair in appearance and / or structure.
  • the object is achieved by the provision of cosmetic compositions containing a. EUK-134 and / or EUK-1 18 and b. at least one care substance.
  • the cosmetic contains EUK-134 and / or EUK-1 18 and at least one care substance in a physiologically acceptable carrier.
  • EUK-134 or the agents according to the invention for influencing the natural pigmentation process of the skin and / or skin appendages.
  • EUK-134 is used.
  • the cosmetic compositions according to the invention show improved care effects on the skin and on the hair.
  • Hair treatment compositions for the purposes of the present invention are, for example, hair dyes, bleaching agents, hair shampoos, hair conditioners, conditioning shampoos, hairsprays, hair conditioners, hair treatments, hair wraps, hair tonics, perming solutions, hair coloring shampoos, hair dyes, hair fixatives, hair dressings, hair styling preparations, hair waving Lotions, mousses, hair gels, hair waxes or combinations thereof.
  • Particularly preferred hair treatment agents are characterized in that they are formulated as shampoo, hair tonics, hair conditioner, hair conditioner, hair foam, hair setting agent, hair spray, hair gel and / or hair dye.
  • the cosmetic composition EUK-134 and / or EUK-1 contains 18 in a total amount of 0.000001 - 10 wt .-%, preferably 0.00001 - 5 wt .-%, particularly preferably 0.0001 - 2nd Wt .-%, most preferably 0.001 - 1 wt .-%, each based on the total weight of the composition.
  • care substances in particular those active ingredients to understand that have a nourishing effect on the skin and / or hair.
  • Suitable care substances are, for example, conditioning agents, in particular skin and / or hair conditioners, preferably moisturizers, emollients, moisturizers, cell-activating and / or protective substances.
  • Particularly suitable care substances are selected from the group of polymers (preferably cationic and / or amphoteric polymers), plant extracts, vitamins, provitamins or vitamin precursors, carbohydrates, quinones, in particular biochinones, preferably ubiquinones, bisabolol and / or bisaboloxides, taurine, silicones, furanones, herbal Oils, urea and urea derivatives, natural betaines, creatine, ectoine, aH yd roxy carboxylic acid, a-ketocarboxylic acid or ß-hydroxycarboxylic acid or their ester, lactone or salt form, fatty acid triglycerides, flavonoids and / or isoflavonoids.
  • polymers preferably cationic and / or amphoteric polymers
  • plant extracts preferably cationic and / or amphoteric polymers
  • vitamins preferably ubiquinones, bisabolol and / or bisaboloxides, taurine
  • Preferred conditioners are selected from the group monosaccharides, disaccharides, oligosaccharides, taurine, carnitine, carnitine derivatives, creatine, ectoine, panthenol and pantolactone.
  • Particularly preferred care substances are selected from panthenol, pantolactone and / or carnitine or carnitine derivatives.
  • the cosmetic agent contains the at least one care substance in a total amount of 0.000001 to 10 wt.%, Preferably 0.00001 to 5 wt.%, Particularly preferably 0.0001 to 2 wt preferably 0.001 to 1 wt .-%, each based on the total weight of the composition. If more than one of the above care products is combined, the stated quantities apply to the total amount of these care substances.
  • the care substance contained according to the invention is preferably at least one hair conditioning agent selected from cationic polymers, cationic surfactants, silicones and / or vegetable oils.
  • compositions according to the invention are vitamins, provitamins or vitamin precursors. These are described below:
  • vitamin A The group of substances referred to as vitamin A include retinol (vitamin A-1) and 3,4-didehydroretinol (vitamin A 2 ).
  • the ß-carotene is the provitamin of retinol.
  • vitamin A component according to the invention for example, vitamin A acid and its esters, vitamin A aldehyde and vitamin A alcohol and its esters such as the palmitate and the acetate into consideration.
  • the agents according to the invention preferably contain the vitamin A component in amounts of 0.05-1% by weight, based on the total preparation.
  • the vitamin B group or the vitamin B complex include, inter alia, vitamin B (thiamine), vitamin B 2 (riboflavin), vitamin B 3 .
  • the compounds nicotinic acid and nicotinamide are often performed.
  • Preferred according to the invention is the nicotinic acid amide which is contained in the agents used according to the invention preferably in amounts of from 0.05 to 1% by weight, based on the total agent.
  • vitamin B 5 pantothenic acid, panthenol and pantolactone. Panthenol and / or pantolactone are preferably used in the context of this group.
  • Derivatives of panthenol which can be used according to the invention are, in particular, the esters and ethers of panthenol and also cationically derivatized panthenols.
  • panthenol triacetate the panthenol monoethyl ether and its monoacetate and also the cationic panthenol derivatives disclosed in WO 92/13829.
  • the said compounds of the vitamin B 5 type are preferably contained in the agents according to the invention in amounts of 0.05-10% by weight, based on the total agent. Amounts of 0, 1-5 wt .-% are particularly preferred.
  • vitamin B 6 pyridoxine and pyridoxamine and pyridoxal
  • Vitamin C ascorbic acid
  • Vitamin C is used in the agents according to the invention preferably in amounts of 0.1 to 3 wt .-%, based on the total agent.
  • Vitamin E tocopherols, especially ⁇ -tocopherol.
  • Tocopherol and its derivatives which include in particular the esters such as the acetate, the nicotinate, the phosphate and the succinate, are preferably present in the agents according to the invention in amounts of 0.05-1% by weight, based on the total agent.
  • Vitamin F The term "vitamin F" is usually understood as meaning essential fatty acids, in particular linoleic acid, linolenic acid and arachidonic acid. Vitamin H.
  • Vitamin H is the compound (3aS, 4S, 6aR) -2-oxohexahydrothienol [3,4-c] imidazole-4-valeric acid, for which, however, the trivial name biotin has become established.
  • Biotin is preferably present in the compositions according to the invention in amounts of from 0.0001 to 1.0% by weight, in particular in amounts of from 0.001 to 0.01% by weight.
  • cosmetic agents according to the invention in particular hair treatment compositions, which additionally contain as care substance - based on its weight - 0.1 to 5 wt .-%, preferably 0.2 to 4 wt .-%, particularly preferably 0.25 to 3.5 Wt .-%, more preferably 0.5 to 3 wt .-% and in particular 0.5 to 2.5 wt .-% vitamins and / or pro-vitamins and / or vitamin precursors contain, preferably the groups A, B, C, E, F and H, with preferred agents being panthenol (( ⁇ ) -2,4-dihydroxy-A / - (3-hydroxypropyl) -3,3-dimethylbutyramide, provitamin B 5 ) and / or pantothenic acid (Vitamin B 3 , vitamin B 5 ) and / or niacin, niacinamide or nicotinamide (vitamin B 3 ) and / or L-as
  • Agents preferred according to the invention contain as care substance - based on their weight - 0.01 to 15 wt .-%, preferably 0.025 to 12.5 wt .-%, particularly preferably 0.05 to 10 wt .-%, more preferably 0, 1 to 7.5% by weight and in particular 0.5 to 5% by weight of at least one 2-furanone derivative of the formula (Fur I) and / or of the formula (Fur-II)
  • R as a -C 2 -C 4 -saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, -C 2 -C 4 -saturated or mono- or diunsaturated, branched or linear mono- , Di- or trihydroxyhydrocarbyl radical,
  • R 2 and R 3 each independently represent hydrogen, a methyl, a C 2 -C 4 -saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, a -C 2 -C 4 -saturated or mono- or diunsaturated, branched or linear mono-, di- or trihydroxyhydrocarbyl radical,
  • R 4 is hydrogen, a methyl, a C 2 -C 4 -saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, a -C 2 -C 4 -saturated hydrocarbon radical, or diunsaturated, branched or linear mono-, di- or trihydroxyhydrocarbon hydrocarbon radical, a -C 2 -C 4 -saturated or mono- or diunsaturated, branched or linear mono-, di- or triaminocarbyl radical,
  • R 5 and R 6 each represent hydrogen, methyl, a C 2 -C 4 -saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, a -C 2 -C 4 - saturated mono- or diunsaturated, branched or linear mono-, di- or trihydroxyhydrocarbyl radical, a -C 2 -C 4 -saturated or mono- or diunsaturated, branched or linear mono-, di- or triaminocarbon radical, a group -COR 16 , where R 6 is a methyl, a C 2 -C 4 -saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, a -C 2 -C 4
  • R 7 is a methyl, a C 2 -C 30 -saturated or mono- or polyunsaturated, branched or linear hydrocarbon radical, a -C 2
  • the compound corresponding to the formula (Fur-I) is (R) - (-) - 4-hydroxymethyl-T-butyrolactone and / or D, L-4-hydroxymethyl- ⁇ -butyrolactone and / or (S) - (+) - 4-hydroxymethyl- ⁇ -butyrolactone and / or R - (-) - 2-hydroxy-3,3-dimethyl- ⁇ -butyrolactone and / or D, L-2-hydroxy-3 , 3-dimethyl- ⁇ -butyrolactone and / or S (+) - 2-hydroxy-3,3-dimethyl- ⁇ -butyrolactone and / or 4-hydroxy-2,5-dimethyl-3 (2H) -furanone and / or tetra
  • Further particularly preferred combinations are agents or the use of 0.000001 - 10 wt .-% EUK-134 with 0.000001 - 10 wt .-% pantolactone; 0.000001 - 10 wt .-% EUK-1 18 with 0.000001 - 10 wt .-% pantolactone, 0.000001 - 10 wt .-% (EUK-134 and EUK-1 18) with 0,000001 - 10th % By weight of pantolactone.
  • compositions according to the invention comprise at least one natural betaine compound.
  • Natural betaine compounds according to the invention are naturally occurring compounds with the atomic grouping R 3 N + -CH 2 -X-COO " according to IUPAC rule C-816.1 So-called betaine surfactants (synthetic) do not fall under the betaine compounds used according to the invention, just as no other zwitterionic compounds where the positive charge on N or P and the negative charge are formally O, S, B or C, but do not conform to IUPAC Rule C-816.1
  • compositions according to the invention are characterized in that they comprise at least one natural betaine compound in a total amount of 0.05 to 5 wt.%, Preferably 0, 1 to 3 wt.%, Particularly preferably 0.5 to 2 wt. , in each case based on the total composition.
  • a particularly preferred care substance selected from natural betaines is carnitine (3-hydroxy-4- (trimethylammonium) -butyric acid betaine, [(R) -3-carboxy-2-hydroxypropyl] -trimethylammonium betaine), more preferably L-carnitine.
  • carnitine derivatives can also be used.
  • Preferred carnitine derivatives are in particular selected from carnitine tartrate, acetyl carnitine, carnitine fumarate, carnitine citrate,
  • Lauroyl carnitine and most preferably carnitine tartrate are particularly preferred.
  • Carnitine derivatives Acetyl-L-carnitine, L-carnitine fumarate, L-carnitine citrate, lauroyl-L-carnitine and especially preferred L-carnitine tartrate.
  • the L-carnitine compounds mentioned are available, for example, from Lonza GmbH (Wuppertal, Germany).
  • carnitine and / or the carnitine derivative is added to the cosmetic agent in a total amount of 0.000001-10% by weight, preferably 0.00001.
  • 0.000001 - 10 wt% EUK-134 0.000001 to 10% by weight of carnitine tartrate and 0.000001 to 10% by weight of pantolactone
  • 0.000001 - 10 wt% EUK-1 18 0.000001 - 10% by weight of carnitine tartrate; with 0.000001-10% by weight of pantolactone
  • 0.000001 - 10 wt% (EUK-134 and EUK-1 18) 0.000001 - 10 wt% carnitine tartrate and with 0.000001 - 10 wt% pantolactone
  • the compositions according to the invention contain ectoine.
  • Ectoin is the common name for 2-methyl-1, 4,5,6-tetrahydropyrimidine-4-carboxylate.
  • ectoine is preferred in amounts of from 0.000001 to 10% by weight, in particular 0.00001 to% by weight, preferably 0.0001 to 1% by weight, particularly preferably 0.001 to 0.5% by weight and exceptionally preferably 0.005 to 0.01 wt .-%, each based on the total composition.
  • 0.000001 - 10 wt .-% EUK-134 agents or the use of 0.000001 - 10 wt .-% EUK-134; 0.000001 - 10% by weight ectoine and with 0.000001 - 10% by weight panthenol; 0.000001 - 10 wt% EUK-1 18; 0.000001 - 10% by weight ectoine; with 0.000001-10% by weight of panthenol; 0.000001 - 10 wt% (EUK-134 and EUK-1 18), 0.000001 - 10 wt% ectoine and 0.000001 - 10 wt% panthenol; 0.000001 - 10 wt% EUK-134; 0.000001 - 10% by weight of ectoine and with 0.000001 - 10% by weight of pantolactone; 0.000001 - 10 wt% EUK-1 18; 0.000001 - 10% by weight ectoine; with 0.000001-10% by weight of pantolactone;
  • the compositions according to the invention contain creatine.
  • Creatine is the common name for / V-methyl-guanidinoacetic acid or / V-amidinosarcosine.
  • creatine is preferred in amounts of from 0.0001 to 1% by weight, especially preferably 0.001 to 0.5 wt .-% and most preferably 0.01 to 0, 1 wt .-%, each based on the total composition.
  • 0.000001 - 10 wt .-% EUK-134 agents or the use of 0.000001 - 10 wt .-% EUK-134; 0.000001 to 10% by weight of creatine and 0.000001 to 10% by weight of panthenol; 0.000001 - 10 wt% EUK-118; 0.000001 - 10 wt% creatine; with 0.000001-10% by weight of panthenol; 0.000001 - 10 wt% (EUK-134 and EUK-1 18), 0.000001 - 10 wt% creatine and 0.000001 - 10 wt% panthenol; 0.000001 - 10 wt% EUK-134; 0.000001 to 10% by weight of creatine and 0.000001 to 10% by weight of pantolactone; 0.000001 - 10 wt% EUK-1 18; 0.000001 - 10% by weight creatine; with 0.000001-10% by weight of pantolactone; 0.000001 - 10 wt% (EUK-134 and EU
  • compositions according to the invention are characterized in that at least one alkyl- or hydroxyalkyl-substituted urea of the general formula (A) is present to improve skin moisture while omitting comedogenic substances.
  • R 1 , R 2 , R 3 and R 4 independently of one another represent a hydrogen atom, a methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert.
  • Butyl or C 2 -C 6 -hydroxyalkyl group which is substituted by 1 to 5 hydroxyl groups or Ci-C4-hydroxyalkyl groups are, with the proviso that at least one of the radicals R- ⁇ - R 4 is a C 2 -C 6 -Hydroxyalkyl group substituted with 1 to 5 hydroxyl groups or CrC 4 -hydroxyalkyl groups.
  • compositions according to the invention are characterized in that the at least one alkyl or hydroxyalkyl-substituted urea of the general formula (A) is selected from compounds in which R 1 , R 2 , R 3 and R 4 independently of one another represent a hydrogen atom, a methyl , Ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert.
  • Butyl or C 2 -C 6 hydroxyalkyl group which is substituted by 1 to 5 hydroxyl groups or Ci-C4-hydroxyalkyl groups are, with the proviso that at least one of the radicals R and R 2 and at least simultaneously one of R 3 and R 4 is a C 2 -C 6 hydroxyalkyl group substituted with 1 to 5 hydroxyl groups or C 1 -C 4 hydroxyalkyl groups.
  • Further preferred compositions according to the invention are characterized in that the at least one alkyl or hydroxyalkyl-substituted urea of the general formula (A) is selected from bis- ⁇ , ⁇ '- (2-hydroxyethyl) urea.
  • compositions according to the invention are characterized in that they contain at least one alkyl- or hydroxyalkyl-substituted urea of the formula (A), in particular N, N'-bis (2-hydroxyethyl) urea, in a total amount of 0.01-50% by weight. %, preferably 0.1 to 20 wt .-%, particularly preferably 1 to 10 wt .-% and most preferably 2 to 5 wt .-%, based on the total composition.
  • A alkyl- or hydroxyalkyl-substituted urea of the formula (A), in particular N, N'-bis (2-hydroxyethyl) urea
  • N, N'-bis- (2-hydroxyethyl) urea a crystalline solid at room temperature
  • Hydrovance commercial product from the National Starch and Chemical Company as an approximately 45-55% aqueous solution containing urea and ammonium lactate.
  • compositions according to the invention contain as a care substance at least one olive leaf extract (Olea Europaea (Olive) Leaf Extract).
  • Olea Europaea (Olive) Leaf Extract An inventively particularly preferred olive leaf extract is available under the trade name Oleanoline DPG from the company Vincience.
  • Another invention particularly preferred olive leaf extract is under the trade name Olea europ Fol extr. S. sicc. available from Fruitarom.
  • compositions according to the invention are characterized in that they contain at least one olive leaf extract in a total amount of from 0.01 to 5% by weight, preferably from 0.1 to 3% by weight and more preferably from 0.5 to 1 to 2% by weight. %, in each case based on the extract as a commercial product tel quel in the entire composition according to the invention.
  • Olive leaf extracts may have a high content of oleanolic acid and / or oleanol.
  • the compositions according to the invention contain oleanolic acid, oleanol and / or oleuropein.
  • compositions according to the invention are characterized in that they contain oleanolic acid, oleanol and / or oleuropein in a total amount of 0.00001 to 2% by weight, preferably 0.001 to 1% by weight and more preferably 0.05 to 0.1% by weight .-%, in each case based on the total composition of the invention.
  • compositions according to the invention contain ursolic acid as a care substance.
  • Compositions which are particularly preferred according to the invention are characterized in that they comprise ursolic acid in a total amount of 0.00001 to 2% by weight, preferably 0.001 to 1% by weight and more preferably 0.05 to 0.1% by weight, in each case to the entire composition of the invention.
  • the agents according to the invention may contain at least one carbohydrate, preferably selected from the group of monosaccharides, disaccharides and / or oligosaccharides.
  • preferred cosmetic agents in particular hair treatment compositions, are characterized in that they have a care substance - based on their weight - 0.01 to 5 wt .-%, preferably 0.05 to 4.5 wt .-%, particularly preferably 0.1 to 4% by weight, more preferably 0.5 to 3.5% by weight and in particular 0.75 to 2.5% by weight
  • Carbohydrate (s) selected from monosaccharides, disaccharides and / or oligosaccharides, preferred carbohydrates being selected from
  • Monosaccharides (in particular D-ribose and / or D-xylose and / or L-arabinose and / or D-glucose and / or D-mannose and / or D-galactose and / or D-fructose and / or sorbose and / or L-fucose and / or L-rhamnose)
  • Disaccharides in particular sucrose and / or maltose and / or lactose and / or trehalose and / or cellobiose and / or gentiobiose and / or isomaltose.
  • compositions to be used according to the invention contain based on their weight
  • compositions to be used according to the invention contain based on their weight
  • the agents according to the invention may therefore contain from 0.0001 to 5% by weight of at least one biochinone of the formula (Ubi)
  • X, Y, Z are independently -O- or -NH- or NR 4 - or a chemical bond
  • R, R 2 , R 3 independently of one another represent a hydrogen atom or an optionally substituted aryl group or an optionally substituted (C 1 -C 6) -alkyl group or a hydroxyalkyl group or a polyhydroxyalkyl group or an optionally substituted (d-Ce) -alkylene group, or a ( C 1 -C 6) -acyl radical, preferred radicals being selected independently of one another from -H, CH 3, -CH 2 CH 3, - (CH 2) 2 CH 2, -CH (CH 3) 2, - (CH 2) 3 CH 3, -CH (CH 3) CH 2 CH 3, CH 2 CH (CH 3 ) 2 , -C (CH 3 ) 3
  • R 4 is -CH 3 , -CH 2 CH 3 , - (CH 2 ) 2 CH 2 , -CH (CH 3 ) 2 ,
  • n stands for values from 1 to 20, preferably from 2 to 15 and in particular for 5, 6, 7, 8, 9, 10.
  • Particularly preferred cosmetic agents according to the invention are characterized in that they contain as care substance - based on their weight - 0.0001 to 1 wt .-%, preferably 0.001 to 0.5 wt .-% and particularly preferably 0.005 to 0, 1% by weight of at least one ubiquinone and / or at least one ubiquinol and / or at least one derivative of these substances, with preferred agents containing a ubiquinone of the formula (Ubi)
  • n 6, 7, 8, 9 or 10, particularly preferably 10 (coenzyme Q10).
  • Particularly preferred agents according to the invention or compositions to be used according to the invention contain based on their weight
  • compositions according to the invention or agents to be used according to the invention contain by weight
  • the agents according to the invention may also contain plastoquinones.
  • preferred agents according to the invention are characterized in that they are 0.0002 to 4 wt .-%, preferably 0.0005 to 3 wt .-%, particularly preferably 0.001 to 2 wt .-%, more preferably 0.0015 to 1 and in particular 0.002 to 0.5 wt .-% of at least one plastoquinone of the formula (Ubi-Ib)
  • n stands for values of 1 to 20, preferably of 2 to 15 and in particular for 5, 6, 7, 8, 9, 10, whereby particularly preferred means Plastochinon PQ-9 of the formula
  • the agents according to the invention may preferably also contain plant extracts (L) as care substance (s). Usually these extracts are produced by extraction of the whole plant. However, in individual cases it may also be preferred to prepare the extracts exclusively from flowers and / or leaves of the plant.
  • L plant extracts
  • s care substance
  • extracts of green tea, almond, aloe vera, coconut, mango, apricot, lime, wheat, kiwi and melon are especially suitable for the use according to the invention.
  • alcohols and mixtures thereof can be used as extraction agent for the preparation of said plant extracts water.
  • the alcohols are lower alcohols such as ethanol and isopropanol, but especially polyhydric alcohols such as ethylene glycol and propylene glycol, both as sole extractant and in admixture with water, are preferred.
  • Plant extracts based on water / propylene glycol in a ratio of 1:10 to 10: 1 have proven to be particularly suitable.
  • the plant extracts can be used according to the invention both in pure and in diluted form. If they are used in diluted form, they usually contain about 2 to 80 wt .-% of active substance and as a solvent used in their extraction agent or extractant mixture.
  • compositions according to the invention mixtures of several, especially two, different plant extracts.
  • compositions according to the invention or the compositions used according to the invention comprise at least one flavonoid or at least one flavonoid-rich plant extract.
  • the flavonoids preferred according to the invention include the glycosides of the flavones, the flavanones, the 3-hydroxyflavones (flavonols), the aurones and the isoflavones.
  • Particularly preferred flavonoids are selected from naringin (aurantiine, naringenin-7-rhamnoglucoside), ⁇ -glucosylrutin, ⁇ -glucosylmyricetin, ⁇ -glucosylisoquercetin, ⁇ -glucosylquercetin, dihydroquercetin (Taxifolin), hesperidin (3 ', 5J-trihydroxy-4'- methoxyflavanone-7-rhamnoglucoside, hesperetin-7-O-rhamnoglucoside), neohesperidin, rutin (3,3 ', 4', 5,7-pentahydroxy-flavone-3-rhamnoglucoside, quercetin-3-r
  • Extremely preferred flavonoids according to the invention are ⁇ -glucosylrutin, naringin and apigenin-7-glucoside. Also preferred are those constructed from two flavonoid units Biflavonoids, the z. B. occur in gingko species. Other preferred flavonoids are the chalcones, especially phloricin, hesperidin methyl chalcone and neohesperidin dihydrochalcone.
  • compositions according to the invention are characterized in that they contain at least one flavonoid in a total amount of from 0.0001 to 1% by weight, preferably from 0.0005 to 0.5% by weight and more preferably from 0.001 to 0.1% by weight. %, in each case based on the Flavo- noiditsubstanz in the entire cosmetic composition.
  • compositions according to the invention or the compositions used according to the invention contain at least one isoflavonoid or at least one isoflavonoid-rich plant extract.
  • the isoflavones and the isoflavone glycosides are counted at this point as isoflavonoids.
  • isoflavones are to be understood as meaning substances which are hydrogenation, oxidation or substitution products of 3-phenyl-4H-1-benzopyran, hydrogenation of which may be in the 2,3-position of the carbon skeleton, oxidation under Formation of a carbonyl group in the 4-position may be present, and by substitution of the replacement of one or more hydrogen atoms by hydroxy or methoxy groups to understand.
  • the isoflavones preferred according to the invention include, for example, daidzein, genistein, prunetin, biochanin, orobol, santal, pratense, irigenin, glycitein, biochanin A and formononetin.
  • Particularly preferred isoflavones are daidzein, genistein, glycitein and formononetin.
  • the isoflavones are glycosidically linked via at least one hydroxy group to at least one sugar.
  • Suitable sugars are mono- or oligosaccharides, in particular D-glucose, D-galactose, D-glucuronic acid, D-galacturonic acid, D-xylose, D-apiose, L-rhamnose, L-arabinose and rutinose.
  • Particularly preferred isoflavone glycosides according to the invention are daidzin and genistin.
  • the isoflavones and / or their glycosides are contained in the preparations as constituents of a substance mixture obtained from a plant, in particular a plant extract.
  • a substance mixture obtained from a plant in particular a plant extract.
  • Such vegetable substance mixtures can be obtained in a manner familiar to the person skilled in the art, for example by squeezing or extracting from plants such as soya, red clover or chickpeas.
  • Isoflavones or isoflavone glycosides in the form of extracts obtained from soybean are particularly preferably used in the preparations according to the invention, as described, for example, under the product name Soy Protein Isolate SPI (Protein Technology International, St.
  • apple seed extract contains phytohormones, isoflavonoids, phytosterols, triterpenoids, tocopherols and natural waxes.
  • compositions according to the invention are characterized in that they contain at least one isoflavonoid in a total amount of 0.00001 to 1% by weight, preferably 0.0005 to 0.5% by weight and more preferably 0.001 to 0.1% by weight. %, in each case based on the Isoflavonoiditsubstanz in the entire cosmetic composition.
  • compositions according to the invention contain, in addition to the active ingredient combination according to the invention, at least one ⁇ -hydroxycarboxylic acid, ⁇ -ketocarboxylic acid or ⁇ -hydroxycarboxylic acid or their ester, lactone or salt form.
  • Preferred ⁇ -hydroxycarboxylic acids or ⁇ -ketocarboxylic acids according to the invention are glycolic acid, lactic acid, tartaric acid, citric acid, 2-hydroxybutanoic acid, 2,3-dihydroxypropanoic acid, 2-hydroxypentanoic acid, 2-hydroxyhexanoic acid, 2-hydroxyheptanoic acid, 2-hydroxyoctanoic acid, 2-hydroxydecanoic acid, Hydroxydodecanoic acid, 2-hydroxytetradecanoic acid, 2-hydroxyhexadecanoic acid, 2-hydroxyoctadecanoic acid, mandelic acid, 4-hydroxymandelic acid, malic acid, erythraric acid, threaric acid, glucaric acid, galactaric acid, mannaric acid, gular acid, 2-hydroxy-2-methyl-succinic acid, gluconic acid, Pyruvic acid, glucuronic acid and galacturonic acid.
  • Particularly preferred ⁇ -hydroxycarboxylic acids are lactic acid, citric acid, glycolic acid and gluconic acid.
  • a particularly preferred ⁇ -hydroxycarboxylic acid is salicylic acid.
  • the esters of said acids are selected from the methyl, ethyl, propyl, isopropyl, butyl, amyl, pentyl, hexyl, 2-ethylhexyl, octyl, decyl, dodecyl and hexadecyl esters.
  • compositions according to the invention are characterized in that in addition to the active ingredient combination according to the invention at least one ⁇ -hydroxycarboxylic acid, ⁇ -ketocarboxylic acid and / or ⁇ -hydroxycarboxylic acid or a derivative, in particular an ester, a lactone or a Salt thereof, in a total amount of 0.01 to 10 wt .-%, preferably 0 1 to 5 wt .-%, particularly preferably 0.5 to 1 to 2 wt .-%, each based on the total composition ,
  • the agent according to the invention of the first subject of the invention contains as care substance at least one fatty acid triglyceride or fatty acid triglyceride mixture, preferably with a high proportion of unsaturated fatty acids.
  • a fatty acid triglyceride is a triester of glycerol with three different or identical fatty acids.
  • the fatty acid according to the invention is an aliphatic carboxylic acid having a long, almost exclusively unbranched carbon chain and a chain length of 8 to 30 carbon atoms.
  • the fatty acids of the fatty acid triglycerides may carry saturated or unsaturated carbon chains, wherein at least 80 wt .-% of the fatty acids contained in the triglyceride must be at least monounsaturated and therefore must have at least one C-C double bond.
  • Unsaturated fatty acids may have a double bond in their carbon chain both in (E) and in (Z) configuration, with multiple double bonds in the fatty acid, both fatty acids with double bonds exclusively in (ZJ configuration, exclusively in (E) configuration or can also be used in mixed configuration, but preferred are unsaturated fatty acids with all-fZJ configuration.
  • Preferred unsaturated fatty acids according to the invention are palmitoleic acid (C16: 1 9Z), oleic acid (C18: 1 9Z), elaidic acid (C18: 1 9E), eicosenoic acid (gondoic acid, C20: 1 1 1Z), erucic acid (C22: 1 13Z), nervonic acid ( C24: 1 15Z), linoleic acid (C18: 2 9Z12Z), Y- (gamma) -linolenic acid (C18: 3 6Z9Z12Z), o (alpha) -linolenic acid (C18: 3 9Z12Z15Z), ⁇ -elaeostearic acid (C18: 3 9Z, 1 1 E, 13E) and arachidonic acid (C20: 4 5Z8Z1 1Z14Z).
  • the fatty acid triglycerides or fatty acid triglyceride mixtures which can be used according to the invention can, however, also contain proportionally esters of saturated fatty acids with glycerol in addition to esters with unsaturated fatty acids.
  • the composition preferably contains mixtures of fatty acid triglycerides, wherein glycerol is esterified with different unsaturated and saturated fatty acids, as long as it is ensured that the molar proportion of unsaturated fatty acids at least 80 wt .-%, preferably at least 85 wt .-% and particularly preferably at least 88 % By weight, based in each case on the total weight of all fatty acids of the fatty acid triglyceride or fatty acid triglyceride mixture.
  • Preferred fatty acid triglycerides which can be used according to the invention are a mixture of fatty acid triglycerides, which is distinguished by the proportion of Y- (gamma) -linolenic acid (C18: 3 c6c9c12; also (a / - Z) -6,9,12-octatrienoic acid ) Among the fatty acids at least 15 wt .-%, preferably at least 18 wt .-% and in particular at least 20 wt .-%, each based on the total weight of all fatty acids of the fatty acid triglyceride or fatty acid triglyceride mixture is.
  • compositions according to the invention contain as fatty acid triglycerides or fatty acid triglyceride mixture with a high proportion of unsaturated fatty acids.
  • a measure of the unsaturation of a compound or of a mixture of compounds is the so-called iodine number. especially for mixtures, determine the proportion of CC double bonds, where a high number stands for a high proportion of double bonds.
  • the person skilled in the determination of the iodine number is well known, it can for example be determined by the method DGF CV-1 1 b.
  • fatty acid triglycerides or fatty acid triglyceride mixtures which have an iodine number of at least 125, preferably of at least 130 and in particular of 130 to 150.
  • fatty acid triglyceride mixtures which have a proportion of ⁇ -linolenic acid of at least 15% by weight, based on the total weight of all fatty acids of the fatty acid triglyceride mixture, and an iodine number of at least 125.
  • Suitable fatty acid triglycerides or fatty acid triglyceride mixtures according to the invention are, in particular, natural oils which have the abovementioned features, which are preferably of vegetable origin.
  • An embodiment of the first subject of the invention is therefore characterized in that the fatty acid triglyceride or fatty acid triglyceride mixture in the form of a natural, vegetable oil is used in the composition according to the invention.
  • the vegetable oil has been found to be particularly suitable from the seeds of European woody plants, in particular from Borago officinalis L. (borage).
  • Borage oil is obtained either by mechanical pressing from the seeds of Borago officinalis L. and subsequent refining as a fatty oil or by extraction and subsequent refining, preference being given to oil obtained by compression, in particular by cold pressing.
  • a further embodiment of the first subject of the invention is therefore characterized in that the agent contains as fatty acid triglyceride or fatty acid triglyceride mixture the oil from seeds of Borago officinalis L. (borage).
  • Agents preferred according to the invention are characterized in that the agent comprises the fatty acid triglyceride or fatty acid triglyceride mixture with a proportion of unsaturated fatty acids of at least 80% by weight, based on the total weight of all fatty acids of the fatty acid triglyceride or fatty acid triglyceride mixture, in a proportion of 0.01 to 10% by weight. -%, preferably from 0.05 to 5 wt .-% and in particular from 0, 1 to 3 wt .-%, each based on the total weight of the ready-to-use agent contains.
  • the agents according to the invention may contain further active ingredients and adjuvants. These are described below.
  • the agents according to the invention preferably additionally comprise at least one emulsifier or a surfactant, surface-active substances being referred to as surfactants or as emulsifiers, depending on the field of use, and selected from anionic, cationic, zwitterionic, ampholytic and nonionic surfactants and emulsifiers.
  • Agents preferred according to the invention are characterized in that they contain, based on their weight, from 0.5 to 70% by weight, preferably from 1 to 60% by weight and in particular from 5 to 25% by weight of anionic and / or nonionic (s) and / or cationic and / or amphoteric surfactant (s).
  • Preferred anionic surfactants and emulsifiers are acylglutamates, acyl isethionates, acyl sarcosinates and acyl taurates, each with a linear or branched acyl radical having 6 to 22 carbon atoms and 0, 1, 2 or 3 double bonds, which in particularly preferred embodiments of an octanoyl, decanoyl, lauroyl , Myristoyl, palmitoyl and stearoyl radical, esters of tartaric acid, citric acid or succinic acid or of the salts of these acids with alkylated glucose, in particular the products with the INCI name Disodium Coco-Glucoside Citrate, Sodium Coco-Glucoside Tartrate and Disodium Coco-glucosides sulfosuccinates, alkyl polyglycol ether sulfates and ether carboxylic acids having 8 to 18 carbon atoms in the alkyl group and up to 12 ethoxy groups in the
  • Zwitterionic surfactants and emulsifiers are surface-active compounds which contain at least one quaternary ammonium group and at least one in the molecule - carry or -S0 3 ⁇ _) group - COO ⁇ _).
  • Particularly suitable zwitterionic surfactants and emulsifiers are the so-called betaines, such as N-alkyl-N, N-dimethylammonium glycinates, for example cocoalkyldimethylammonium glycinate, N-acylaminopropyl-N, N-dimethylammonium glycinates, for example cocoacylaminopropyldimethylammonium glycinate, and 2-alkyl-3 carboxymethyl-3-hydroxyethyl-imidazolines each having 8 to 18 carbon atoms in the alkyl or acyl group, and the cocoacylaminoethylhydroxyethylcarboxymethylglycinate.
  • Ampholytic surfactants and emulsifiers are surface-active compounds which, apart from a C 8 - contain at least one free amino group and at least one -COOH or -S0 3 H group and alkyl or acyl group capable of forming inner salts - C 2 4 are.
  • ampholytic surfactants are N-alkylglycines, N-alkylaminopropionic acids, N-alkylaminobutyric acids, N-alkyliminodipropionic acids, N-hydroxyethyl-N-alkylamidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids and alkylaminoacetic acids each having about 8 to 24 C atoms in the alkyl group.
  • Particularly preferred ampholytic surfactants are N-cocoalkylaminopropionate, cocoacylaminoethylaminopropionate and the d 2 -C 8 -acylsarcosine.
  • cationic surfactants of the quaternary ammonium compound type are ammonium halides, in particular chlorides and bromides, such as alkyltrimethylammonium chlorides, dialkyldimethylammonium chlorides and trialkylmethylammonium chlorides.
  • the long alkyl chains of these surfactants preferably have 10 to 18 carbon atoms, such as.
  • cetyl trimethyl ammonium chloride stearyl trimethyl ammonium chloride, distearyl dimethyl ammonium chloride, lauryl dimethyl ammonium chloride, lauryl dimethyl benzyl ammonium chloride and tricetylmethyl ammonium chloride.
  • Further preferred cationic surfactants are the imidazolium compounds known under the INCI names Quaternium-27 and Quaternium-83.
  • 18 - fatty alcohol ethoxylate (s) having from 12 to 20 EO units, preferably in amounts of from 5 to 20% by weight, preferably from 7.5 to 17.5% by weight and in particular from 10 to 15% by weight, each based on the weight of the agent included.
  • hair treatment compositions which contain, based on their weight, from 0.1 to 20% by weight, preferably from 0.25 to 17.5% by weight and in particular from 5 to 15% by weight of anionic ( s) surfactant (s), particularly preferably fatty alcohol ether sulfates of the formula
  • n represents values of from 5 to 21, preferably from 7 to 19, particularly preferably from 9 to 17 and in particular from 1 to 13 and k for values of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, preferably 1, 2 or 3 and especially 2
  • M is a cation from the group Na + , K + NH 4 + , Mg 2+ , Zn 2+ , preferably Na + ,
  • Preferred cosmetic agents according to the invention are further characterized in that they additionally contain amphoteric surfactant (s), preferably from the groups of N-alkylglycines, N-alkylpropionic acids, N-alkylaminobutyric acids, N-alkylimidodipropionic acids, N-hydroxyethyl N-alkylamidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids each having about 8 to 24 carbon atoms in the alkyl group, alkylaminoacetic acids each having about 8 to 24 carbon atoms in the alkyl group, N-cocoalkylaminopropionate, cocoacylaminoethylaminopropionate C 2 - C 8 - acyl sarcosine, N-alkyl-N, N-dimethylammonium glycinates, for example cocoalky
  • Preferred cosmetic agents according to the invention in particular hair treatment compositions, contain as amphoteric T.
  • R is a straight-chain or branched, saturated or mono- or polyunsaturated alkyl or alkenyl radical having 8 to 24 carbon atoms
  • surfactants are referred to the INCI nomenclature as Amidopropylbetaine, wherein the representatives derived from coconut fatty acids are preferred and are referred to as Cocoamidopropylbetaine.
  • surfactants of the formula (I) which are a mixture of the following representatives:
  • agents according to the invention are preferred which, based on their weight, are from 0.25 to 8% by weight, more preferably from 0.5 to 7% by weight, more preferably from 0.75 to 6.5% by weight and in particular 1 to 5.5 wt .-% of surfactant (s) of the formula (I).
  • the cosmetic compositions according to the invention in particular hair treatment compositions, with particular preference as amphoteric surfactants, can be betaines of the formula (II)
  • R is a straight-chain or branched, saturated or mono- or polyunsaturated alkyl or alkenyl radical having 8 to 24 carbon atoms.
  • surfactants are referred to according to the INCI nomenclature as amphoacetates, wherein the representatives derived from coconut fatty acids are preferred and are referred to as cocoamphoactetates.
  • agents according to the invention are preferred which, based on their weight, are from 0.25 to 8% by weight, more preferably from 0.5 to 7% by weight, more preferably from 0.75 to 6.5% by weight and in particular 1 to 5.5 wt .-% of surfactant (s) of the formula (VII).
  • nonionic surfactants are alkyl polyglycosides.
  • cosmetic agents according to the invention in particular hair treatment compositions are preferred which contain as nonionic surfactants alkyl polyglycosides of the general formula RO- (Z) x , where R is alkyl, Z is sugar and x is the number of sugar units.
  • Alkylpolyglycosides are nonionic surfactants made entirely from renewable resources (sugar building blocks, predominantly glucose, for example from corn starch and fatty alcohol, for example from coconut oil). Alkyl polyglycosides are accessible by acid-catalyzed reaction (Fischer reaction) of sugars, especially glucose (or starch) or butyl glycosides with fatty alcohols.
  • alkyl monoglucoside alkyl- ⁇ -D- and ⁇ -D-glucopyranoside and small amounts of glucofuranoside
  • alkyldiglucosides -isomaltosides, maltosides, etc.
  • alkyl oligoglucosides maltotriosides, tetraosides, etc.
  • the average degree of polymerization of commercial products whose alkyl radicals are in the range C8-C16 is 1, 2-1, 5.
  • alkylpolyglycosides corresponding to the general formula RO - (Z) x , where R is alkyl, Z is sugar and x is the number of sugar units.
  • R is alkyl
  • Z is sugar
  • x is the number of sugar units.
  • Ci 2 - to Ci6-alkyl groups consisting essentially of Ci 2 - to Ci6-alkyl groups or
  • sugar building block Z it is possible to use any desired mono- or oligosaccharides.
  • sugars with 5 or 6 carbon atoms and the corresponding oligosaccharides are used.
  • Such sugars are, for example, glucose, fructose, galactose, arabinose, ribose, xylose, lyxose, allose, altrose, mannose, gulose, idose, talose and sucrose.
  • Preferred sugar building blocks are glucose, fructose, galactose, arabinose and sucrose; Glucose is particularly preferred.
  • alkylpolyglycosides which can be used according to the invention contain on average 1, 1 to 5 sugar units. Alkyl polyglycosides having x values of 1.1 to 2.0 are preferred. Very particular preference is given to alkyl glycosides in which x is 1: 1 to 1, 8.
  • the agents according to the invention may also contain anionic, cationic and optionally also further amphoteric or zwitterionic or nonionic surfactants.
  • the agents according to the invention may contain from 0.01 to 10% by weight of at least one polymer from the group of cationic and / or amphoteric polymers.
  • the polymer or polymers are used within narrower ranges.
  • agents according to the invention are preferred which, based on their weight, are from 0.05 to 7.5% by weight, preferably from 0.1 to 5% by weight, more preferably from 0.2 to 3.5% by weight and in particular from 0.25 to 2.5% by weight of amphoteric polymer (s).
  • agents contain amphoteric polymers or not
  • further preferred agents according to the invention are characterized in that they contain, based on their weight, from 0.05 to 7.5% by weight, preferably from 0.1 to 5% by weight. -%, particularly preferably 0.2 to 3.5 wt .-% and in particular 0.25 to 2.5 wt .-% cationic (s) polymer (s) included.
  • Preferred cationic polymers are, for example
  • Celquat ® quaternized cellulose derivatives, such as are available under the names of Celquat ® and Polymer JR ® commercially.
  • JR® 400 are preferred quaternized cellulose derivatives
  • honey for example the commercial product Honeyquat ® 50,
  • cationic guar derivatives in particular those sold under the tradename Cosmedia Guar ® and Jaguar ® products,
  • Such compounds are sold under the names Gafquat ® 734 and Gafquat ® 755 commercially,
  • Vinylpyrrolidone vinylimidazoliummethochloride copolymers such as those offered under the names Luviquat.RTM ® FC 370, FC 550, FC 905 and HM 552,
  • Polyquaternium 2 Polyquaternium 17, Polyquaternium 18 and Polyquaternium 27 with quaternary nitrogen atoms in the polymer main chain.
  • Can be used as cationic polymers are sold under the names Polyquaternium-24 (commercial product z. B. Quatrisoft ® LM 200), known polymers.
  • copolymers of vinylpyrrolidone such as the commercial products Copolymer 845 (manufactured by ISP), Gaffix ® VC 713 (manufactured by ISP), Gafquat ® ASCP 101 1, Gafquat ® HS 1 10, Luviquat ® 8155 and Luviquat ® MS 370 are available.
  • Cationic protein hydrolysates may also be used as cationic polymers, preferred agents being one or more cationic protein hydrolyzates from the group Cocodimonium Hydroxypropyl Hydrolyzed Collagen, Cocodimonium Hydroxypropyl Hydrolyzed Casein, Cocodimonium Hydroxypropyl Hydrolyzed Collagen, Cocodimonium Hydroxypropyl Hydrolyzed Hair Keratin, Cocodimonium Hydroxypropyl Hydrolyzed Keratin, Cocodimonium Hydroxypropyl Hydrolyzed Rice Protein, Cocodimonium Hydroxypropyl Hydrolyzed Soy Protein, Cocodimonium Hydroxypropyl Hydrolyzed Wheat Protein, Hydroxypropyl Arginine Lauryl / Myristyl Ether HCl, Hydroxypropyltrimonium Gelatin, Hydroxypropyltrimonium Hydrolyzed Casein, Hydroxypropyltrimonium Hydrolyzed Collagen, Hydroxypropyltrimonium Hydrolyzed Con
  • hair treatment compositions which - based on their weight - 0.05 to 7.5 wt .-%, preferably 0.1 to 5 wt .-%, particularly preferably 0.2 to 3.5 wt cationic polymer (s), with preferred cationic polymer (s) being selected from poly (methacryloyloxyethyltrimethylammonium chloride) (INCI: Polyquaternium -37) and / or; quaternized cellulose derivatives (INCI: Polyquaternium 10) and / or cationic alkylpolyglycosides and / or cationized honey and / or cationic guar derivatives and / or polymeric dimethyldiallylammonium salts and their copolymers with esters and amides of acrylic acid and methacrylic acid and / or copolymers of vinylpyrrolidone with quaternized derivatives of dialkylaminoalkyl acryl
  • the agents of the invention may contain amphoteric polymers.
  • agents according to the invention are preferred. in which the amphoteric polymer (s) co-polymers of at least one of the monomers trimethylammoniumethylacrylamide and / or trimethylammoniumethylmethacrylamide and / or trimethylammoniumpropylacrylamide and / or trimethylammoniumpropylmethacrylamide and / or trimethylammoniumethylacrylamide and / or trimethylammoniumethylacrylamide and / or trimethylammoniumethylacrylate and / or trimethylammoniumethylmethacrylate and / or trimethylammoniumethylacrylat and or ethyldimethylammoniumethylacrylamide and / or ethyldimethylammoniumethylmethacrylamide and / or ethyldimethylammoniumpropylacrylamide and / or
  • the agents according to the invention additionally contain polymers, proteins, protein hydrolysates and / or amino acids in addition to the at least one care substance.
  • the agents according to the invention may with particular preference contain one or more amino acids.
  • Particularly preferred amino acids which can be used according to the invention are from the group glycine, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, proline, aspartic acid, glutamic acid, asparagine, glutamine, serine, threonine, cysteine, methionine, lysine, arginine, histidine, ⁇ Alanine, 4-aminobutyric acid (GABA), betaine, L-cystine (L-Cyss), L-citrulline, L-theanine, 3 ', 4'-dihydroxy-L-phenylalanine (L-dopa), 5'-hydroxy L-tryptophan, L-homocysteine, S-methyl-L-methionine, S-allyl-L-cysteine-s
  • Preferred agents according to the invention contain, in addition to EUK-134 and / or EUK-1 18 and at least one care substance, one or more amino acids in narrower quantitative ranges.
  • preferred cosmetic agents in particular hair treatment compositions, are characterized in that they contain, based on their weight, from 0.01 to 5% by weight, preferably from 0.02 to 2.5% by weight, particularly preferably from 0.05 to 1 , 5 wt .-%, more preferably 0.075 to 1 wt .-% and in particular 0, 1 to 0.25 wt .-% amino acid (s), preferably from the group glycine and / or alanine and / or valine and / or Lysine and / or leucine and / or threonine included.
  • Particularly preferred agents according to the invention contain based on their weight
  • hair treatment compositions contain as care substance - based on their weight - 0.01 to 15 wt .-%, preferably 0.025 to 12.5 wt .-%, particularly preferably 0.05 to 10 wt .-%, further preferably 0, 1 to 7.5 wt .-% and in particular 0.5 to 5 wt .-% taurine (2-aminoethanesulfonic acid).
  • cosmetic agents according to the invention in particular hair treatment compositions are preferred which additionally 0.001 to 5 wt .-%, preferably 0.01 to 4 wt .-%, particularly preferably 0.02 to 2.5 wt .-% and in particular 0.1 to 1, 5 wt .-% bisabolol and / or oxides of bisabolol, preferably (-) - contain alpha-bisabolol.
  • compositions according to the invention may contain, in addition to the care substances, further substances which prevent, alleviate or heal hair loss.
  • a content of hair root stabilizing agents is advantageous.
  • cosmetic agents according to the invention are preferred which additionally contain, based on their weight, from 0.001 to 5% by weight.
  • Hair root stabilizing substances in particular minoxidil and / or finasteride and / or ketoconazole included.
  • Additional antidandruff active ingredients for example climbazole, piroctone olamine or zinc pyrithione
  • climbazole, piroctone olamine or zinc pyrithione are used to purposefully reduce the amount of dandruff causing the dandruff, to restore the normal bacterial count to the normal percentage and to reduce the scaling to the physiological level.
  • laboratory tests have shown that the different species representatives of Pityrosporum ovale react differently to the antidandruff active ingredients. In order to maximally combat all dandruff is therefore a combination of anti-dandruff active ingredients most successful.
  • agents according to the invention which additionally contain, based on their weight, from 0.001 to 5% by weight of antidandruff active ingredients, in particular piroctone olamine (1-hydroxy-4-methyl-6- (2,4,4-tri-methylpentyl) -pyridine-2 ( 1 H) -one, compound with 2-aminoethanol, 1: 1) and / or zinc pyrithione and / or selenium sulfide and / or climbazole and / or salicylic acid or fumaric acid.
  • antidandruff active ingredients in particular piroctone olamine (1-hydroxy-4-methyl-6- (2,4,4-tri-methylpentyl) -pyridine-2 ( 1 H) -one, compound with 2-aminoethanol, 1: 1) and / or zinc pyrithione and / or selenium sulfide and / or climbazole and / or salicylic acid or fumaric acid.
  • a preferred form of preparation of the cosmetic agent according to the invention takes place in the form of hair tonics or hair lotions.
  • These preferably contain besides EUK-134 and / or EUK-1 18 and at least one care substance at least one monohydric alcohol and optionally contain a gelling agent.
  • a further subject of the present invention is a cosmetic agent, in particular hair treatment agent containing
  • compositions according to the invention contain from 0.1 to 90% by weight of at least one monohydric alcohol from the group of ethanol, n-propanol, isoporopanol, n-butanol.
  • ethanol and / or isopropanol are particularly preferred.
  • Particularly preferred cosmetic agents according to the invention, in particular hair treatment compositions are characterized in that they contain, based on their weight, from 0.5 to 85% by weight, preferably from 1 to 80% by weight, particularly preferably from 5 to 75% by weight preferably 10 to 70 wt .-% and in particular 25 to 60 wt .-% ethanol and / or isopropanol.
  • Particularly preferred cosmetic agents in particular hair treatment compositions, contain exclusively ethanol.
  • cosmetic agents according to the invention in particular hair treatment compositions, which - based on their weight - 5 to 80 wt .-%, preferably 7.5 to 70 wt .-%, particularly preferably 10 to 60 wt .-%, more preferably 20 to 55 Wt .-% and in particular 25 to 50 wt .-% ethanol, more preferably.
  • agents according to the invention may additionally contain a gelling agent.
  • a gelling agent Through the use of these gelling agents, the adhesion of the agents on the hair can be improved and the application can be made more pleasant.
  • agents according to the invention in particular hair treatment agents, which are - based on their weight - 0, 15 to 9 wt .-%, preferably 0.2 to 8 wt .-%, particularly preferably 0.25 to 7 wt .-%, further preferably 0.3 to 6 wt .-% and in particular 0.4 to 5 wt .-% of at least one gelling agent from the groups of silicas and / or layered silicates and / or organo-layer silicates and / or metal soaps and / or hardened castor oil and / or modified fat Derivatives and / or polyamides and / or hydroxyethylcellulose (HEC) and / or carboxymethylcellulose (CMC) and / or hydroxypropylmethylcellulose (HPMC)
  • compositions according to the invention in particular also the hair lotions and / or hair tonics according to the invention, may contain emulsifiers (F).
  • the agents according to the invention may contain emulsifiers (F).
  • Hydrophilic emulsifiers preferably form O / W emulsions and hydrophobic emulsifiers preferably form W / O emulsions.
  • An emulsion is to be understood as meaning a droplet-like distribution (dispersion) of a liquid in another liquid under the expense of energy in order to create stabilizing phase interfaces by means of surfactants.
  • the selection of these emulsifying surfactants or emulsifiers depends on the substances to be dispersed and the respective outer phase and the fineness of the emulsion.
  • the agents according to the invention preferably contain the emulsifiers in amounts of 0.1-25% by weight, in particular 0.5-15% by weight, based on the total agent.
  • compositions according to the invention may preferably contain at least one nonionic emulsifier having an HLB value of 8 to 18.
  • Nonionic emulsifiers having an HLB value of 10 to 15 may be particularly preferred according to the invention.
  • the anionic polymers (G2) are anionic polymers which have carboxylate and / or sulfonate groups.
  • anionic monomers from which such polymers may consist are acrylic acid, methacrylic acid, crotonic acid, maleic anhydride and 2-acrylamido-2-methylpropanesulfonic acid.
  • the acidic groups may be wholly or partly present as sodium, potassium, ammonium, mono- or triethanolammonium salt.
  • Preferred monomers are 2-acrylamido-2-methylpropanesulfonic acid and acrylic acid.
  • Anionic polymers which contain 2-acrylamido-2-methylpropanesulfonic acid as the sole or co-monomer can be found to be particularly effective, it being possible for the sulfonic acid group to be wholly or partly present as sodium, potassium, ammonium, mono- or triethanolammonium salt ,
  • the homopolymer of 2-acrylamido-2-methyl propane sulfonic acid which is commercially available, for example under the name Rheothik ® 1 1-80 is.
  • Suitable nonionic polymers are, for example: 'vinylpyrrolidone / Vinylester copolymers, cellulose ethers such as hydroxypropyl cellulose, hydroxyethyl cellulose and Methylhy- hydroxypropylcellulose, starch and its derivatives, in particular starch, shellac, polyvinyl siloxanes. Glycosidically substituted silicones.
  • the preparations comprise a plurality of, in particular two, different polymers of the same charge and / or in each case an ionic and an amphoteric and / or nonionic polymer.
  • the other polymers (G) are contained in the agents according to the invention preferably in amounts of 0.05 to 10 wt .-%, based on the total agent. Amounts of 0, 1 to 5, in particular from 0.1 to 3 wt .-%, are particularly preferred.
  • an agent according to the invention may also contain UV filters (I).
  • the UV filters to be used according to the invention are not subject to any general restrictions with regard to their structure and their physical properties. On the contrary, all UV filters which can be used in the cosmetics sector and whose absorption maximum lies in the UVA (315-400 nm), in the UVB (280-315 nm) or in the UVC ( ⁇ 280 nm) range are suitable. UV filters with an absorption maximum in the UVB range, in particular in the range from about 280 to about 300 nm, are particularly preferred.
  • the UV filters (I) are contained in the compositions according to the invention usually in amounts of 0.1-5 wt .-%, based on the total agent. Levels of 0.4-2.5 wt .-% are preferred.
  • compositions of the invention may further contain a 2-pyrrolidinone-5-carboxylic acid and its derivatives (J).
  • a 2-pyrrolidinone-5-carboxylic acid and its derivatives Preference is given to the sodium, potassium, calcium, magnesium or ammonium salts in which the ammonium ion carries, in addition to hydrogen, one to three C 1 to C 4 alkyl groups.
  • the sodium salt is most preferred.
  • the amounts used in the compositions according to the invention are preferably from 0.05 to 10% by weight, based on the total agent, more preferably 0, 1 to 5, and especially 0.1 to 3% by weight.
  • a particularly preferred group of care agents are the silicones.
  • Particularly preferred compositions according to the invention comprise the silicone (s) preferably in amounts of from 0.1 to 10% by weight, preferably from 0.25 to 7% by weight and in particular from 0.5 to 5% by weight. , in each case based on the total mean.
  • Agents preferred according to the invention are characterized in that, based on their weight, they contain 0.01 to 10% by weight, preferably 0.1 to 8% by weight, more preferably 0.25 to 7.5% by weight and in particular 0, 5 to 5 wt.% Amino-functional silicone (s) included.
  • compositions according to the invention have advantageous properties and also confer advantageous properties on the hair treated with them. Benefits have been observed especially in hair and scalp treatment.
  • cosmetic agents according to the invention in particular hair treatment compositions, increase the elasticity of the hair treated with them and lead to an inner-structural strengthening of the hair fibers, which can be obtained, for example, from reflected in higher melting temperatures in differential thermal analysis.
  • compositions according to the invention cause an increase in the elasticity and, surprisingly, sebum-regulating effects. The visual impression of "greasy" skin or hair is thus avoided or weakened.
  • Another object of the present invention is the use of cosmetic agents according to the invention, in particular hair treatment compositions, for improving at least one of the properties
  • a further subject of the present invention is the use of EUK-134 and / or EUK-1 18 the agents according to the invention for influencing the natural pigmentation process of skin and / or skin appendages.
  • the term "influencing the natural pigmentation process” means the positive or negative influence on the natural coloration / coloring and / or pigmentation of the skin and / or skin appendages, in particular the stimulation or the partial or complete inhibition of the natural, i. understood biological pigmentation process in skin and / or skin appendages, in particular hair or hair follicles.
  • the skin, the mucosa, the hair and its hair follicles, glands and nails especially skin, mucous membranes, hair and hair follicles to understand.
  • the term skin is particularly preferably to be understood as meaning the skin without mucous membrane.
  • Hair or hair follicles, preferably body hair, beard hair and head hair are very particularly preferred under the term skin appendages especially preferably beard hair and head hair, very particularly preferably hair on the head or the corresponding hair follicles.
  • the influencing of the natural pigmentation process means the positive or negative influencing at least one partial step of the natural pigmentation process.
  • This influence relates in particular to the regulation of such molecular signals that influence the biological or natural pigmentation process.
  • the regulation of the biological or natural pigmentation process by gene regulation i. the regulation at the expression level, and / or enzyme regulation, i. the regulation at the activity level, and / or the regulation at the hormone level.
  • gene regulation i. the regulation at the expression level
  • enzyme regulation i. the regulation at the activity level
  • regulation at the hormone level particularly preferred is the regulation of melanogenesis, in particular in the melanocytes, preferably of the hair, inter alia, the regulation of gene expression of MCR1 (melanocortin receptor 1), gp100 and ckit.
  • MCR1 melanocortin receptor 1
  • gp100 gp100
  • ckit the regulation of tyrosinase
  • the regulation at the enzyme level includes.l
  • the natural pigmentation process of the hair is influenced, in particular stimulated or stimulated.
  • the positive influence preferably the positive regulation (upregulation or activation or excitation or increase) is understood as influencing, which leads to a stimulation of the natural, biological pigmentation process.
  • Particularly preferred as regulation at the hormone level is the induction of melanogenesis-stimulating hormones, in particular alpha-MSH and / or ACTH (corticotrophin, adrenocorticotropin, adrenocorticotropic hormone).
  • an enzyme-level regulation e.g., tyrosinase
  • stimulation especially increase in the amount and / or activity of the enzyme (e.g., tyrosinase), as well as any other form of stimulation.
  • the pigmentation process in particular the melanogenesis, the skin and the skin appendages, preferably the hair or the hair follicle
  • the natural pigmentation process in particular melanogenesis
  • the melanogenesis is preferably influenced in the melanocytes, particularly preferably the hair or the hair follicle.
  • a mere increase in the number of vital, viable or melanocytes capable of producing melanin in the hair follicle or the increase in their general vitality is preferably not included.
  • the pigmentation process, preferably the melanogenesis, of the human hair or of the human hair follicle is influenced.
  • the stimulation, enhancement, stimulation or improvement of the melanin synthesis in the melanocytes is particularly preferred according to the invention.
  • This is achieved, for example, by an increase in gene expression of signaling molecules such as MCR1 (Melanocortin receptor 1), gp100 and ckit achieved.
  • the influence, preferably stimulation, of the melanogenesis is achieved by the use according to the invention.
  • melanogenesis, in particular in the melanocytes is preferably stimulated in the hair or hair follicles of the hairy scalp and / or the beard, in particular in humans.
  • the stimulation of the pigmentation means in particular, the improvement, enhancement and / or stimulation of the transport of the melanosomes into the keratinocytes surrounding the hair follicle, and furthermore the pigmentation of the individual hair perceptible with the eye or correspondingly suitable measuring methods, a selection of hairs , in particular an area of hairy skin, in particular the scalp, or of the entire head and / or whisker.
  • compositions according to the invention or the use of EUK-134 and / or EUK-1 18 are suitable for stimulating or improving the pigmentation of the hair.
  • the hair is maintained during the application (improved).
  • hair granulation, in particular of human hair is prevented, preferably substantially prevented, and / or reduced by the compositions according to the invention or the use of EUK-134 and / or EUK-1 18.
  • hair graying is understood as meaning both the hair graying which is visually discernible by the mixture of white and pigmented hair and the pigment dilution in a single hair, that is to say the graying of a single hair.
  • a prevention of hair graying takes place especially in hair not grayed, a reduction in hair graying can take place both in already grayed as well as hair not yet graying.
  • hair follicles in which the melanogenesis is not, no longer or not completely or disturbed or reduced again stimulated / stimulated to melanogenesis, while in non-grayed hair / hair follicles a disorder, reduction or down-regulation of melanogenesis not first or only to a lesser extent.
  • hair that has already been grayed out is repigmented by the use according to the invention of EUK-134 and / or EUK-1 18 or the agents according to the invention.
  • the use according to the invention is a cosmetic use which is non-therapeutic.
  • the use according to the invention which aims at the hair growth caused by the natural aging process, in particular non-diseased hair graying, is a purely cosmetic use which does not represent a treatment and / or prophylaxis of a disease, thus being non-therapeutic.
  • the use according to the invention takes place topically, ie by application to the skin and / or skin appendages, in particular the face and / or scalp, in particular the scalp.
  • already gray hair is repigmented by the use according to the invention of EUK-134 and / or EUK-1 18 or the agents according to the invention.
  • the agents according to the invention or the use of EUK-134 and / or EUK-1 18 are capable of positively influencing the natural pigmentation process, in particular in the hair or hair follicle, in particular stimulate.
  • the combination according to the invention induced both gene expression of MCR-1 and that of ckit and gp100 in a synergistic manner.
  • a synergistic increase in melanin synthesis was observed.
  • the natural pigmentation process can thus be influenced, in particular stimulated, by the skin and / or skin appendages.
  • this can be used to influence, in particular stimulate, the natural pigmentation process of the hair, the hair follicle or in the hair follicle.
  • the compositions used in the invention are suitable for stimulating and / or improving the pigmentation of the hair, stimulating melanogenesis, in particular in the hair follicle, preventing and / or reducing hair graying, and repigmenting grayed hair.
  • Another object of the present invention is a method for influencing the natural pigmentation process of skin and / or skin appendages, in particular stimulation of the natural pigmentation process, in particular melanogenesis, preferably in melanocytes, and / or the pigmentation of the hair, for preventing and / or reducing hair graying and / or repigmentation of grayed hair, characterized in that EUK-134 and / or EUK-1 18 is brought into contact with hair and / or skin topically.
  • Example 1 is intended to illustrate the subject matter of the invention without limiting it.
  • Example 1 is intended to illustrate the subject matter of the invention without limiting it.
  • the ligands involved in melanogenesis such as SCF or alpha-MSH (melanocyte stimulating hormone alpha) bind to various receptors, by which the corresponding signal is transmitted to the cell interior.
  • the receptor for SCF is ckit
  • the receptor for alpha-MSH is MCR-1 (melanocortin receptor 1).
  • MCR-1 melanocortin receptor 1
  • Gp100 is a protein found and stabilized in the membrane of melanosomes. Since melanin is increasingly produced in the cells after the application of substances that have a positive influence on melanogenesis, there is an increase in the number of melanosomes required for transport. A substance that induces gene expression of gp100 is therefore a pigment stimulating agent.
  • Particularly preferred substances which stimulate the natural pigmentation process of skin and / or skin appendages, in particular hair or hair follicles, are those which both cause gene expression of MCR-1 and / or ckit and also induce gene expression of gp100.
  • the determination of the extent of the change in gene expression after administration of such substances to suitable cells / cell systems / tissue cultures can provide information about the effectiveness of the active ingredient.
  • RNA from the organotypic cell cultures is first isolated with the aid of the RNeasy Mini Kit from Qiagen and transcribed into cDNA by means of reverse transcription.
  • the formation of the PCR products is detected online via a fluorescence signal.
  • the fluorescence signal is proportional to the amount of the PCR product formed. The stronger the expression of a particular gene, the greater the amount of PCR product produced and the higher the fluorescence signal.
  • the untreated control is set equal to 1 and the expression of the genes to be determined referred to (x-fold expression). Values greater than or equal to 1.8 times the expression or less than or equal to 0.5 times the expression of the untreated control are classified as significantly differentially expressed. Values greater than or equal to 1.5-fold expression or less than or equal to the O-fold expression of the untreated control are considered to tend to be differentially expressed.
  • gp100 In addition to the induction of gene expression, translation into the corresponding proteins is also important for influencing cellular mechanisms.
  • the expression of gp100 was therefore additionally detected at the protein level by Western Blot technique.
  • Melanin is a dye that is produced and stored in the melanosomes of melanocytes. Melanin gives the hair its true color, whereby the coloration is produced by a mixture of two types of melanin, eu- and pheomelanin. Melanogenesis is a complicated and often regulated synthesis process. First, tyrosine is converted by the enzyme tyrosinase into L-dihydroxyphenylalanine (L-DOPA) and then through several intermediate steps in the various melanin pigments.
  • L-DOPA L-dihydroxyphenylalanine
  • An active agent which positively influences melanogenesis and leads to an increased melanin content in hair follicle melanocytes is particularly suitable for influencing the natural pigmentation process of skin and / or skin appendages, preventing hair graying and / or stimulating pigmentation.
  • Table 3 Melanin content in organotypic hair follicle cell cultures after treatment with EUK-134
  • the melanin content of the organotypic hair follicle cell cultures could be induced compared to the untreated control.
  • the values differ highly significantly (p-value determined by Student t-test), at a use concentration of 0.1% significantly from the control value.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne des produits cosmétiques, contenant EUK-134 et/ou EUK-118, et au moins une substance traitante, ainsi que l'utilisation de EUK-134 et/ou EUK-118 pour agir sur le processus de pigmentation naturelle de la peau et/ou des appendices cutanés.
PCT/EP2010/061811 2009-12-18 2010-08-13 Produit cosmétique, contenant euk-134 et/ou euk-118, et au moins une substance traitante Ceased WO2011079971A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009054980.3 2009-12-18
DE200910054980 DE102009054980A1 (de) 2009-12-18 2009-12-18 Kosmetische Mittel, enthaltend EUK-134 und/oder EUK-118 und mindestens einen Pflegestoff

Publications (2)

Publication Number Publication Date
WO2011079971A2 true WO2011079971A2 (fr) 2011-07-07
WO2011079971A3 WO2011079971A3 (fr) 2012-06-14

Family

ID=43598293

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/061811 Ceased WO2011079971A2 (fr) 2009-12-18 2010-08-13 Produit cosmétique, contenant euk-134 et/ou euk-118, et au moins une substance traitante

Country Status (2)

Country Link
DE (1) DE102009054980A1 (fr)
WO (1) WO2011079971A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202016003916U1 (de) 2015-06-29 2016-10-11 Hans Werner Bierganns Emulsion
CN116172937A (zh) * 2023-03-14 2023-05-30 陕西慧康生物科技有限责任公司 含euk-134对抗光老化及光损伤的组合物及应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102695901B1 (ko) * 2023-07-24 2024-08-19 (주)한솔바이오텍 줄댕강나무 추출물을 이용한 피부 미백용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013829A1 (fr) 1991-02-06 1992-08-20 Smith Ronald J Composes quaternaires de panthenol et utilisation desdits composes
WO2003103616A2 (fr) 2002-06-11 2003-12-18 L'oreal Utilisation d'un agent mimetique de l'activite de la dopachrome tautomerase (trp-2) comme agent protecteur des melanocytes du follicule pileux et applications

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3725030A1 (de) 1987-07-29 1989-02-09 Henkel Kgaa Oberflaechenaktive hydroxysulfonate
DE4413686C2 (de) 1994-04-20 1996-10-24 Henkel Kgaa Kationische Zuckertenside, Verfahren zu ihrer Herstellung und deren Verwendung
FR2840531B1 (fr) * 2002-06-11 2004-10-29 Oreal Composition cosmetique comprenant un agent mimetique de l'activite de la dopachrome tautomerase (trp-2) pour lutter contre la canitie
US7597879B2 (en) * 2002-11-29 2009-10-06 Bioderm Research Sunscreen safety and efficacy enhancement
KR101362619B1 (ko) * 2008-02-20 2014-02-13 이엘씨 매니지먼트 엘엘씨 피부 미백용 국소 조성물 및 방법
EP2113242A1 (fr) * 2008-05-02 2009-11-04 Pangaea Laboratories Limited Antioxydant destiné à une utilisation dans des préparations cosmétiques, médicamenteuses et pharmaceutiques
GB2460054B (en) * 2008-05-14 2010-11-24 Nb Labs Ltd A skin anti-aging formulation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013829A1 (fr) 1991-02-06 1992-08-20 Smith Ronald J Composes quaternaires de panthenol et utilisation desdits composes
WO2003103616A2 (fr) 2002-06-11 2003-12-18 L'oreal Utilisation d'un agent mimetique de l'activite de la dopachrome tautomerase (trp-2) comme agent protecteur des melanocytes du follicule pileux et applications

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202016003916U1 (de) 2015-06-29 2016-10-11 Hans Werner Bierganns Emulsion
CN116172937A (zh) * 2023-03-14 2023-05-30 陕西慧康生物科技有限责任公司 含euk-134对抗光老化及光损伤的组合物及应用

Also Published As

Publication number Publication date
WO2011079971A3 (fr) 2012-06-14
DE102009054980A1 (de) 2011-06-22

Similar Documents

Publication Publication Date Title
EP2313073B1 (fr) Système de tensioactif doux sans sulfates pour le nettoyage de la peau et des cheveux
DE102009044974A1 (de) Verwendung von Dihydroquercetin und mindestens einer Aminosäure zur positiven Beeinflussung des natürlichen Pigmentierungsprozesses
EP2632422A1 (fr) Combinaison d'actifs et agents pour traiter les cheveux contre les pellicules iii
DE102008020044A1 (de) Pflegendes Haarbehandlungsverfahren
DE102013215434A1 (de) Methionyl-Methionin-Stereoisomere und deren Verwendung in Kosmetika
WO2009024359A1 (fr) Agents de traitement capillaire contenant une ou plusieurs substances de soin et mélatonine/agomélatine
WO2010015517A2 (fr) Agent de lavage et de soin des cheveux contenant des ingrédients bioactifs
WO2012055586A1 (fr) Combinaison d'actifs et agents pour traiter les cheveux contre les pellicules ii
WO2009024360A1 (fr) Agents de traitement capillaire contenant un ou plusieurs tensioactifs et mélatonine/agomélatine
WO2011079971A2 (fr) Produit cosmétique, contenant euk-134 et/ou euk-118, et au moins une substance traitante
DE102013223789A1 (de) Verwendung kosmetischer Zusammensetzungen für die Inaktivierung und/oder Eliminierung von Hautmilben
DE102009044977A1 (de) Kosmetisches Mittel enthaltend Purin und/oder ein Purinderivat und Sclareol
DE102009044970A1 (de) Verwendung von humanem beta-Defensin zur Beeinflussung des natürlichen Pigmentierungsprozesses
WO2009024361A1 (fr) Agents de traitement capillaire contenant un ou plusieurs alcools et de la mélatonine/agomélatine
EP2648691A2 (fr) Association de principes actifs et agent de traitement capillaire
DE102009044964A1 (de) Verwendung einer Kombination aus Carnitin und/oder eines Carnitin-Derivats mit Purin und/oder einem Purin-Derivat zur Beeinflussung des natürlichen Pigmentierungsprozesses
EP2214631B1 (fr) Produits d'hygiène capillaire contenant une association de tensioactifs et d'épaississants
EP2456417A2 (fr) Utilisation de carnitine et de dihydroquercétine pour influencer positivement le processus de pigmentation naturel
DE102010043071A1 (de) Haarbehandlungsmittel mit 3-Methyl-1,3-Butandiol und Alkylpolyglycosid(en)
DE102010043067A1 (de) Haarbehandlungsmittel mit-3-Methyl-1,3-Butandiol und Amphotensid(en)
WO2011009760A1 (fr) Utilisation d'un agent actif d'échinacée pour influencer le processus de pigmentation naturel
DE102008031205A1 (de) Verwendung von natürlichen 1,3-Diolen
DE102009044972A1 (de) Verwendung von mindestens einer Nukleinsäure zur Beeinflussung des natürlichen Pigmentierungsprozesses
DE102011087135A1 (de) Verwendung von Rutin zur Beeinflussung des natürlichen Pigmentierungsprozesses
WO2009083283A1 (fr) Produits de lavage pour cheveux comprenant des agents structurants

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2010741998

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: DE